Ilaria Marcianò

Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study

Ylenia Ingrasciotta, Francesco Giorgianni, Ilaria Marcianò et al. · PLoS ONE · 2016 · 40 citations · Full text

Pharmacy, Hematology, Pharmacology +16

How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014

Ilaria Marcianò, Ylenia Ingrasciotta, Francesco Giorgianni et al. · BioDrugs · 2016 · 35 citations

Medicine, Pharmacology, Pharmacotherapy +12

In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study

Ylenia Ingrasciotta, Viviana Lacava, Ilaria Marcianò et al. · BMC Nephrology · 2019 · 28 citations · Full text

Medicine, Hematology, Nephrology +15

Treatment of Medication-Related Osteonecrosis of the Jaw and its Impact on a Patient’s Quality of Life: A Single-Center, 10-Year Experience from Southern Italy

Giacomo Oteri, Gianluca Trifirò, Matteo Peditto et al. · Drug Safety · 2017 · 26 citations

Dentistry, Maxillofacial Surgery, Oral Surgery +4

Cohort Profile: Burden of Obstructive Lung Disease (BOLD) study

André F.S. Amaral, James Potts, Ben Knox‐Brown et al. · International Journal of Epidemiology · 2023 · 19 citations · Full text

Medicine, Health Sciences, Epidemiology +16